BNTX (BioNTech SE) Moat Score: 8/10 (As of Jul. 03, 2026)


BNTX BioNTech SE BNTX
62 GF Score
Price $97.55
GF Value $88.09
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is BioNTech SE Moat Score?

BioNTech SE BNTX +3.86% 62 Moat Score is 8 as of Jul. 03, 2026. GuruFocus rates BNTX with a GF Score™ of 62/100 and a GF Value™ of $88.09 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,399 Biotechnology companies, BioNTech SE ranks better than 99.93% on this metric.

BioNTech SE has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

BioNTech SE has Wide Moat: BioNTech SE has a robust portfolio of valuable patents and strong R&D capabilities, particularly in mRNA technology. It benefits from significant regulatory barriers and partnerships with major pharmaceutical companies, providing strong pricing power and market leadership in innovative therapies.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioNTech SE might have Wide Moat - Clear and robust wide moat.

BioNTech SE  (NAS:BNTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioNTech SE Moat Score Related Terms

BNTX vs INCY, INSM, ROIV: Moat Score Comparison

For the Biotechnology subindustry, BioNTech SE's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Moat Score distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Moat Score falls into.


BNTX
62GF Score
BioNTech SE BNTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
BioNTech SE (BNTX) has a Moat Score of 8 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioNTech SE ranks #1 out of 1399 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is BioNTech SE's Moat Score too high?
BioNTech SE's current Moat Score is 8. The Biotechnology industry median Moat Score is 2.00. BioNTech SE's value of 8 is 300% above this industry median. Based on the distribution chart, BioNTech SE ranks #1 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Moat Score compare to INCY and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #1 out of 1399 companies for Moat Score. This places BioNTech SE in the top 0% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. BioNTech SE's value of 8 is 300% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNTech SE's current Moat Score of 8 is 300% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $88.09, compared to a current price of $97.55 — trading 10.7% above its estimated fair value. The current Moat Score is 8 and 300% above the Biotechnology industry median of 2.00. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioNTech SE (BNTX), the current Moat Score is 8 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNTech SE (BNTX) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of $97.55 is trading 10.7% above its estimated GF Value™ of $88.09. GuruFocus considers BioNTech SE to be Modestly Overvalued.

Key valuation signals for BNTX:

  • Moat Score: 8
  • GF Value™: $88.09 vs. price of $97.55 (10.7% above fair value)
  • GF Score™: 62/100 with 5 warning signs
  • Industry Position: 300% above the Biotechnology median (#1 of 1399)

No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score

Get the complete analysis for BNTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$97.55
Price
$88.09
GF Value